Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Bruce L Innis

10PUBLICATIONS
63CO-AUTHORS
Nanotoxicology, health and safetyInfant and child healthInnate immunityComputational neuroscience (incl. mathematical neuroscience and theoretical neuroscience)Medical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

Sort by Publication Date:
|Jun 25, 2026
Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai Adults.

|Feb 14, 2025
Infant Responses to Primary Immunization Following Vaccination in Pregnancy With Varying Doses of Recombinant Acellular Pertussis Vaccine Alone or Combined With Tetanus-Diphtheria.

Thanyawee Puthanakit, Kulkanya Chokephaibulkit, Suvaporn Anugulruengkitt

|Nov 26, 2024
Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations.

Darin Zehrung, Bruce L Innis, Auliya A Suwantika

|Nov 11, 2022
Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity.

Min Z Levine, Crystal Holiday, Yaohui Bai

|Oct 28, 2021
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses.

Weina Sun, Yonghong Liu, Fatima Amanat

|Jul 21, 2021
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study.

Joon Hyung Kim, Mamadou Drame, Thanyawee Puthanakit

Pageof 2

Frequent Collaborators

5 joint publications

Florian Krammer

4 joint publications

Adolfo García-Sastre

3 joint publications

Weina Sun

3 joint publications

Peter Palese

3 joint publications

Raffael Nachbagauer

3 joint publications

Corey P Mallett

3 joint publications

Daniel Stadlbauer

2 joint publications

Randy A Albrecht

2 joint publications

Bruno Salaun

2 joint publications

Angela Choi

Frequent Collaborators

5 joint publications

Florian Krammer

4 joint publications

Adolfo García-Sastre

3 joint publications

Weina Sun

3 joint publications

Peter Palese